Reetesh K Pai, MD
Pathology · Johnstown
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · University of Pittsburgh Physicians · 4,166 clinicians in this group
Hospitals listed: Magee Womens Hospital of Upmc Health System · Upmc Presbyterian Shadyside. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Pai’s office at (814) 533-0134 to ask if they take your plan before you enroll.
California Medical Board record
Licence A89127 · Cancelled
Licence status: Cancelled · since 2004 · University of New Mexico School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Magee Womens Hospital of Upmc Health SystemPittsburgh, PAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of UPMC, which runs 34 hospitals in 3 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.464, Oct 2024 – Sep 2025
- Upmc Presbyterian ShadysidePittsburgh, PAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of UPMC, which runs 34 hospitals in 3 statesHome of UPMC Hillman Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.4 (1.22 to 1.57), Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.84 (1.45 to 2.22) · 11,546 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.481, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.755, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.597, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.355, Oct 2024 – Sep 2025
See every measure and the patient survey for Magee Womens Hospital of Upmc Health System
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 8 the same, 0 worse of 8 measures. Readmissions: 1 better, 6 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.464 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 437 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.21 (0.79 to 1.63) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 172.15 (110.62 to 233.69) · 25 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 33 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 859 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,432 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,498 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.85 (1.55 to 6.16) · 569 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.03 (0.34 to 3.71) · 378 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.62 (1 to 4.24) · 563 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.49 (0.02 to 16.96) · 392 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (1.99 to 9.93) · 362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.18) · 158 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.28 (0.24 to 2.33) · 1,064 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 274 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.246 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.593 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.525 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.145 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.39 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -11 · 43 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -42.1 · 34 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 134 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.9 to 5.5) · 2,366 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.7 (10.5 to 13.1) · 2,366 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 229 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.4 · 87 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.1 to 16.1) · 736 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 585 cases | No different | Jan 2024 – Dec 2024 |
What patients said (368 patients answered, 13% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 81% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Upmc Presbyterian Shadyside
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 3 better, 3 the same, 1 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.4 (1.22 to 1.57) | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.84 (1.45 to 2.22) · 11,546 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.481 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.755 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.597 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.355 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0.25 to 1.55) · 4,065 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.94 (137.62 to 198.26) · 391 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.6 · 136 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 156 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.6 · 423 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 718 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 8,785 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.05 to 0.39) · 13,123 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.39 (0.23 to 0.56) · 14,320 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (1.9 to 4.41) · 4,999 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.71 (0.65 to 2.78) · 2,630 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.3 (1.31 to 3.29) · 4,417 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.58 (7.41 to 13.74) · 2,469 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.69 (3.73 to 7.65) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.67 to 3.01) · 1,552 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 387 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.86 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.2 · 664 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23.1 · 1,405 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -2.8 · 212 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -16.5 · 523 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.7 · 425 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.7 · 1,228 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.6 (3.1 to 6.8) · 213 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.1 (5.9 to 10.8) · 213 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.6 · 383 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.7 · 262 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.1 · 439 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.2 (8.8 to 14.2) · 2,561 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 1,016 cases | No different | Jan 2024 – Dec 2024 |
What patients said (612 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$36,530
Medicare paid this office $36,530 for 376 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Pathology examination of tissue using a microscope, intermediate complexity | 302 | $15,408 | $25 |
| Special stained specimen slides to examine tissue, each additional procedure | 67 | $7,465 | $20 |
| Special stained specimen slides to examine tissue, initial procedure | 110 | $3,628 | $26 |
| Pathology examination of tissue using a microscope, high complexity | 15 | $2,977 | $106 |
| Pathology examination of tissue using a microscope, moderately high complexity | 24 | $2,032 | $55 |
See all 10 services
| Pathology examination of tissue using a microscope, intermediate complexity | 302 | $15,408 | $25 |
| Special stained specimen slides to examine tissue, each additional procedure | 67 | $7,465 | $20 |
| Special stained specimen slides to examine tissue, initial procedure | 110 | $3,628 | $26 |
| Pathology examination of tissue using a microscope, high complexity | 15 | $2,977 | $106 |
| Pathology examination of tissue using a microscope, moderately high complexity | 24 | $2,032 | $55 |
| Microscopic genetic analysis of tumor, manual | 29 | $1,407 | $31 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 12 | $783 | $65 |
| Special stained specimen slides to identify organisms including interpretation and report | 13 | $275 | $20 |
| Special stained specimen slides to examine tissue including interpretation and report | 13 | $258 | $9 |
| Pathology examination of tissue using a microscope, moderately low complexity | 21 | $219 | $8 |
Who their Medicare patients are
376 Original Medicare patients in 2024. Average age 71 · Under 65 10% · 85 and older 4% · Women 53% · Also on Medicaid 10% · Health risk score 1.31. At or below the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 70% · Coronary heart disease 30% · Depression 30% · Diabetes 28% · Cancer 27% · Chronic kidney disease 18% · COPD 16% · Atrial fibrillation 15% · Heart failure 13% · Stroke 11% · Dementia 5%.
The office billed $198,666, Medicare allowed $47,742 and paid $36,530; for 1,365 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 376 | 1,365 | 71 | 1.31 | $198,666 | $36,530 |
| 2023 | 359 | 1,272 | 71 | 1.44 | $187,720 | $36,162 |
| 2022 | 451 | 1,419 | 70 | 1.32 | $212,350 | $39,846 |
| 2021 | 380 | 1,351 | 70 | 1.60 | $215,598 | $44,811 |
| 2020 | 335 | 1,333 | 70 | 1.57 | $193,602 | $41,914 |
| 2019 | 361 | 1,260 | 69 | 1.91 | $196,756 | $42,801 |
| 2018 | 415 | 1,367 | 68 | 1.83 | $213,084 | $46,521 |
| 2017 | 421 | 1,415 | 69 | 1.93 | $225,452 | $46,015 |
| 2016 | 383 | 1,248 | 67 | 2.11 | $210,893 | $44,421 |
| 2015 | 350 | 1,148 | 67 | 2.24 | $180,567 | $33,349 |
| 2014 | 423 | 1,253 | 68 | 2.14 | $221,361 | $37,311 |
| 2013 | 318 | 1,042 | 68 | 2.13 | $184,178 | $35,687 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Pathology examination of tissue using a microscope, intermediate complexity | 296 | $17,004 | $27 |
| Special stained specimen slides to examine tissue, each additional procedure | 64 | $5,388 | $22 |
| Special stained specimen slides to examine tissue, initial procedure | 110 | $3,772 | $27 |
| Pathology examination of tissue using a microscope, high complexity | 13 | $3,198 | $110 |
| Pathology examination of tissue using a microscope, moderately high complexity | 25 | $2,101 | $62 |
| Microscopic genetic analysis of tumor, manual | 24 | $1,146 | $32 |
| Pathology examination of specimen during surgery, first tissue block | 14 | $945 | $47 |
| Special stained specimen slides to identify organisms including interpretation and report | 16 | $486 | $20 |
| Pathology examination of tissue using a microscope, moderately low complexity | 29 | $294 | $9 |
2022: 12 services
| Pathology examination of tissue using a microscope, intermediate complexity | 367 | $20,034 | $25 |
| Special stained specimen slides to examine tissue, each additional procedure | 59 | $4,887 | $21 |
| Special stained specimen slides to examine tissue, initial procedure | 124 | $4,082 | $26 |
| Pathology examination of tissue using a microscope, high complexity | 20 | $3,443 | $108 |
| Pathology examination of tissue using a microscope, moderately high complexity | 33 | $2,919 | $63 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 11 | $757 | $69 |
| Microscopic genetic analysis of tumor, manual | 15 | $688 | $33 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 11 | $596 | $54 |
| Special stained specimen slides to identify organisms including interpretation and report | 16 | $541 | $21 |
| Special stained specimen slides to examine tissue including interpretation and report | 14 | $242 | $9 |
| Pathology examination of tissue using a microscope, moderately low complexity | 19 | $224 | $9 |
| Pathology examination of tissue using a microscope | 13 | $66 | $5 |
2021: 12 services
| Pathology examination of tissue using a microscope, intermediate complexity | 289 | $16,922 | $29 |
| Pathology examination of tissue using a microscope, high complexity | 24 | $6,522 | $114 |
| Special stained specimen slides to examine tissue, each additional procedure | 56 | $6,032 | $23 |
| Pathology examination of tissue using a microscope, moderately high complexity | 49 | $5,295 | $65 |
| Special stained specimen slides to examine tissue, initial procedure | 113 | $3,699 | $27 |
| Pathology examination of specimen during surgery, first tissue block | 21 | $1,582 | $49 |
| Microscopic genetic analysis of tumor, manual | 23 | $1,005 | $34 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 14 | $905 | $65 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 12 | $805 | $67 |
| Special stained specimen slides to identify organisms including interpretation and report | 14 | $490 | $20 |
| Pathology examination of tissue using a microscope, moderately low complexity | 38 | $465 | $9 |
| Special stained specimen slides to examine tissue including interpretation and report | 11 | $281 | $10 |
2020: 10 services
| Pathology examination of tissue using a microscope, intermediate complexity | 252 | $15,059 | $29 |
| Special stained specimen slides to examine tissue, each additional procedure | 64 | $8,828 | $23 |
| Pathology examination of tissue using a microscope, moderately high complexity | 45 | $4,720 | $68 |
| Pathology examination of tissue using a microscope, high complexity | 18 | $4,592 | $121 |
| Special stained specimen slides to examine tissue, initial procedure | 120 | $4,219 | $29 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 11 | $796 | $72 |
| Special stained specimen slides to identify organisms including interpretation and report | 16 | $571 | $22 |
| Microscopic genetic analysis of tumor, manual | 13 | $524 | $35 |
| Pathology examination of tissue using a microscope, moderately low complexity | 33 | $406 | $9 |
| Special stained specimen slides to examine tissue including interpretation and report | 17 | $350 | $10 |
2019: 14 services
| Pathology examination of tissue using a microscope, intermediate complexity | 268 | $15,997 | $30 |
| Special stained specimen slides to examine tissue, each additional procedure | 61 | $6,763 | $23 |
| Pathology examination of tissue using a microscope, high complexity | 24 | $5,770 | $118 |
| Special stained specimen slides to examine tissue, initial procedure | 124 | $4,188 | $29 |
| Pathology examination of tissue using a microscope, moderately high complexity | 30 | $3,804 | $68 |
| Pathology examination of specimen during surgery, first tissue block | 14 | $1,128 | $51 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 13 | $931 | $72 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 12 | $821 | $68 |
| Special stained specimen slides to identify organisms including interpretation and report | 24 | $609 | $22 |
| Microscopic genetic analysis of tumor, manual | 12 | $417 | $35 |
| Cell examination of specimen, selective cellular enhancement technique | 13 | $320 | $23 |
| Pathology examination of tissue using a microscope, moderately low complexity | 26 | $317 | $9 |
| Special stained specimen slides to examine tissue including interpretation and report | 11 | $158 | $10 |
| Pathology examination of tissue using a microscope | 11 | $62 | $6 |
2018: 12 services
| Pathology examination of tissue using a microscope, intermediate complexity | 296 | $17,709 | $30 |
| Special stained specimen slides to examine tissue, each additional procedure | 69 | $6,751 | $23 |
| Pathology examination of tissue using a microscope, high complexity | 24 | $5,982 | $120 |
| Pathology examination of tissue using a microscope, moderately high complexity | 51 | $5,463 | $67 |
| Special stained specimen slides to examine tissue, initial procedure | 123 | $4,060 | $29 |
| Pathology examination of specimen during surgery, first tissue block | 17 | $1,533 | $51 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 13 | $916 | $70 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 13 | $795 | $61 |
| Special stained specimen slides to identify organisms including interpretation and report | 15 | $540 | $22 |
| Microscopic genetic analysis of tumor, manual | 14 | $503 | $36 |
| Pathology examination of tissue using a microscope, moderately low complexity | 40 | $399 | $9 |
| Special stained specimen slides to examine tissue including interpretation and report | 12 | $184 | $10 |
2017: 13 services
| Pathology examination of tissue using a microscope, intermediate complexity | 322 | $16,935 | $27 |
| Pathology examination of tissue using a microscope, high complexity | 22 | $6,550 | $119 |
| Special stained specimen slides to examine tissue, each additional procedure | 73 | $6,320 | $23 |
| Special stained specimen slides to examine tissue, initial procedure | 130 | $4,113 | $28 |
| Pathology examination of tissue using a microscope, moderately high complexity | 30 | $3,640 | $67 |
| Evaluation of fine needle aspirate with interpretation and report | 24 | $1,882 | $57 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 15 | $975 | $65 |
| Pathology examination of specimen during surgery, first tissue block | 14 | $962 | $51 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 13 | $872 | $67 |
| Special stained specimen slides to identify organisms including interpretation and report | 32 | $771 | $21 |
| Cell examination of specimen, selective cellular enhancement technique | 30 | $760 | $22 |
| Evaluation of fine needle aspirate | 13 | $438 | $29 |
| Pathology examination of tissue using a microscope, moderately low complexity | 27 | $322 | $9 |
2016: 12 services
| Pathology examination of tissue using a microscope, intermediate complexity | 262 | $15,081 | $29 |
| Pathology examination of tissue using a microscope, high complexity | 25 | $8,403 | $118 |
| Pathology examination of tissue using a microscope, moderately high complexity | 51 | $5,215 | $66 |
| Special stained specimen slides to examine tissue, each additional procedure | 56 | $4,403 | $21 |
| Special stained specimen slides to examine tissue, initial procedure | 99 | $3,234 | $28 |
| Pathology examination of specimen during surgery, first tissue block | 23 | $1,555 | $50 |
| Evaluation of fine needle aspirate with interpretation and report | 18 | $1,420 | $57 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 21 | $1,336 | $64 |
| Cell examination of specimen, selective cellular enhancement technique | 27 | $602 | $22 |
| Special stained specimen slides to identify organisms including interpretation and report | 27 | $591 | $21 |
| Pathology examination of tissue using a microscope, moderately low complexity | 33 | $308 | $9 |
| Special stained specimen slides to examine tissue including interpretation and report | 13 | $231 | $10 |
2015: 11 services
| Pathology examination of tissue using a microscope, intermediate complexity | 247 | $14,090 | $28 |
| Special stained specimen slides to examine tissue, initial procedure | 95 | $3,113 | $27 |
| Special stained specimen slides to examine tissue, each additional procedure | 48 | $3,018 | $16 |
| Pathology examination of tissue using a microscope, high complexity | 13 | $2,791 | $116 |
| Pathology examination of tissue using a microscope, moderately high complexity | 18 | $2,041 | $66 |
| Evaluation of fine needle aspirate with interpretation and report | 30 | $1,989 | $54 |
| Special stained specimen slides to identify organisms including interpretation and report | 52 | $1,297 | $21 |
| Cell examination of specimen, selective cellular enhancement technique | 51 | $1,240 | $22 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 14 | $932 | $67 |
| Evaluation of fine needle aspirate | 11 | $457 | $29 |
| Pathology examination of tissue using a microscope, moderately low complexity | 17 | $227 | $9 |
2014: 12 services
| Pathology examination of tissue using a microscope, intermediate complexity | 284 | $15,430 | $29 |
| Pathology examination of tissue using a microscope, high complexity | 24 | $6,277 | $114 |
| Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain | 103 | $2,688 | $23 |
| Pathology examination of tissue using a microscope, moderately high complexity | 25 | $2,256 | $64 |
| Evaluation of fine needle aspirate with interpretation and report | 38 | $2,209 | $55 |
| Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure) | 65 | $1,914 | $10 |
| Cell examination of specimen, selective cellular enhancement technique | 59 | $1,453 | $22 |
| Special stained specimen slides to identify organisms including interpretation and report | 50 | $1,280 | $21 |
| Pathology examination of specimen during surgery, first tissue block | 13 | $959 | $48 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 12 | $727 | $61 |
| Evaluation of fine needle aspirate | 16 | $443 | $28 |
| Pathology examination of tissue using a microscope, moderately low complexity | 35 | $352 | $9 |
2013: 10 services
| Pathology examination of tissue using a microscope, intermediate complexity | 217 | $12,803 | $28 |
| Special stained specimen slides to examine tissue, initial procedure | 79 | $8,773 | $32 |
| Pathology examination of tissue using a microscope, high complexity | 14 | $3,023 | $112 |
| Pathology examination of tissue using a microscope, moderately high complexity | 30 | $2,786 | $63 |
| Cell examination of specimen, selective cellular enhancement technique | 29 | $1,428 | $45 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 17 | $1,421 | $65 |
| Evaluation of fine needle aspirate with interpretation and report | 23 | $1,403 | $52 |
| Pathology examination of specimen during surgery, first tissue block | 16 | $1,268 | $45 |
| Special stained specimen slides to identify organisms including interpretation and report | 37 | $1,039 | $20 |
| Pathology examination of tissue using a microscope, moderately low complexity | 21 | $226 | $9 |
Medicaid work
$16,785 in 2024
Medicaid paid $16,785 for 249 billed services this clinician did in 2024, up to 46 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| TISSUE EXAM BY PATHOLOGIST | 236 | $16,408 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 13 | $377 |
| 2024 | 249 | 2 | 46 | $16,785 |
| 2023 | 238 | 2 | 39 | $19,340 |
| 2022 | 313 | 2 | 40 | $25,714 |
| 2021 | 176 | 2 | 32 | $16,055 |
| 2020 | 37 | 1 | 19 | $3,478 |
See the largest Medicaid services in earlier years
2023
| TISSUE EXAM BY PATHOLOGIST | 211 | $18,509 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 27 | $831 |
2022
| TISSUE EXAM BY PATHOLOGIST | 256 | $24,080 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 57 | $1,634 |
2021
| TISSUE EXAM BY PATHOLOGIST | 160 | $15,597 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 16 | $458 |
2020
| TISSUE EXAM BY PATHOLOGIST | 37 | $3,478 |
Money from drug and device companies
$8,300 in 2025
| 2025 | 2 | 6 | $8,300 | $8,300 |
| 2024 | 3 | 10 | $56,000 | $56,000 |
| 2023 | 4 | 16 | $31,500 | $31,500 |
| 2022 | 2 | 6 | $26,900 | $26,900 |
| 2020 | 2 | 4 | $35,300 | $35,300 |
| 2019 | 1 | 4 | $5,400 | $5,400 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Velsipity | $7,200 | 5 payments
|
| Arena Pharmaceuticals | Velsipity | $1,100 | 1 payment
|
See all 6 published payments
| Arena Pharmaceuticals | Consulting · 2025-11-12 | Velsipity | $1,100 |
| Pfizer | Consulting · 2025-08-18 | Velsipity | $1,500 |
| Pfizer | Consulting · 2025-05-22 | Velsipity | $1,200 |
| Pfizer | Consulting · 2025-05-22 | Velsipity | $1,500 |
| Pfizer | Consulting · 2025-02-26 | Velsipity | $1,200 |
| Pfizer | Consulting · 2025-02-26 | Velsipity | $1,800 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $56,000
| Arena Pharmaceuticals | Velsipity | $34,100 | 6 payments
|
| Medivation | Velsipity | $12,600 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | None | $9,300 | 1 payment
|
2023: $31,500
| Arena Pharmaceuticals | Velsipity | $23,400 | 8 payments
|
| Pfizer | Litfulo | $3,600 | 4 payments
|
| Boehringer Ingelheim RCV GmbH & Co KG | Spevigo | $3,600 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | None | $900 | 2 payments
|
2022: $26,900
| Pfizer | None | $23,400 | 4 payments
|
| Boehringer Ingelheim RCV GmbH & Co KG | Spevigo | $3,500 | 2 payments
|
2020: $35,300
| Pfizer | None | $33,000 | 3 payments
|
| Boehringer Ingelheim RCV GmbH & Co KG | Pipeline | $2,300 | 1 payment
|
2019: $5,400
| Pfizer | None | $5,400 | 4 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AbbVie Inc. · Rinvoq · 2020 | This clinician | $57,200 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2021 | This clinician | $43,100 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2020 | This clinician | $39,800 |
| ABBVIE INC. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2022 | This clinician | $36,800 |
| Celltrion, Inc. · 2022 | This clinician | $35,600 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2022 | This clinician | $30,300 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2021 | This clinician | $26,500 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2024 | This clinician | $26,100 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study To Evaluate the Efficacy and Safety of Upadacitinib (Abt-494) in Subjects With Moderately To Severely Active Ulcerative Colitis · 2021 | This clinician | $25,300 |
| Eli Lilly and Company · A Phase 3 Multicenter Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2023 | This clinician | $18,000 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Upadacitinib (Abt-494) for Induction and Maintenance Therapy in Subjects With Moderately To Severely Active Ulcerative Colitis · 2021 | This clinician | $16,500 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Subjects With Moderately To Severely Active Crohns Disease Who Have Inadequately Responded To Or Are Intolerant To Biologic Therapy · 2021 | This clinician | $15,900 |
| AbbVie, Inc. · 2019 | This clinician | $14,200 |
| AbbVie Inc. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2023 | This clinician | $14,200 |
| AbbVie Inc. · A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study To Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately To Severely Active Ulcerative Colitis · 2023 | This clinician | $13,100 |
| AbbVie, Inc. · Rinvoq · 2019 | This clinician | $12,900 |
| ABBVIE INC. · A Study of the Efficacy and Safety of Upadacitnib (Abt-494) in Participants With Moderately To Severely Active Crohns Disease Who Have Inadequately Responded To Or Are Intolerant To Conventional and/Or Biologic Therapies · 2022 | This clinician | $12,900 |
| Takeda Pharmaceuticals U.S.A., Inc. · In Active Ulcerative Colitis, A Randomized Controlled Trial for Determination of the Optimal Treatment Target · 2023 | Their institution | $12,740 |
| AbbVie Inc. · Skyrizi · 2020 | This clinician | $11,400 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2022 | This clinician | $9,800 |
| ABBVIE INC. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohns Disease Who Completed the Studies M14-431 Or M14-433 · 2022 | This clinician | $9,300 |
| ABBVIE INC. · A Study of the Efficacy and Safety of Risankizumab in Participants With Crohns Disease · 2022 | This clinician | $9,000 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study To Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately To Severely Active Ulcerative Colitis · 2021 | This clinician | $8,300 |
| Takeda Pharmaceuticals U.S.A., Inc. · Entyvio (Vedolizumab) Long-Term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab To Other Biologic Agents in Patients With Ulcerative Colitis Or Crohn'S Disease · 2023 | Their institution | $8,120 |
| Celltrion, Inc. · 2023 | This clinician | $7,700 |
| Takeda Pharmaceuticals U.S.A., Inc. · In Active Ulcerative Colitis, A Randomized Controlled Trial for Determination of the Optimal Treatment Target · 2024 | Their institution | $7,700 |
| Takeda Pharmaceuticals U.S.A., Inc. · In Active Ulcerative Colitis, A Randomized Controlled Trial for Determination of the Optimal Treatment Target · 2022 | Their institution | $6,930 |
| AbbVie Inc. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohns Disease Who Completed the Studies M14-431 Or M14-433 · 2023 | This clinician | $6,600 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study To Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately To Severely Active Crohns Disease Who Failed Prior Biologic Treatment · 2021 | This clinician | $6,300 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2024 | This clinician | $6,000 |
| Eli Lilly and Company · An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of Ly3471851 (Nktr 358) in Patients With Moderately To Severely Active Ulcerative Colitis · 2022 | This clinician | $5,900 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Double Blind, Randomized, Placebo Controlled, Parallel Group Study To Simultaneosly Qualify A Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due To Alzheimer'S Disease (Mci Due To Ad) and To Test the Safety and Efficacy of Pioglitazone (Ad-4833 Sr 0.8 Mg Qd) To Delay the Onset of Mci Due To Ad in Cognitively Normal Subjects · 2025 | This clinician | $5,610 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2025 | This clinician | $5,500 |
| ABBVIE INC. · A Study To Evaluate the Safety and Efficacy of Upadacitinib (Abt-494) for Induction and Maintenance Therapy in Participants With Moderately To Severely Active Ulcerative Colitis (UC) · 2022 | This clinician | $5,000 |
| ABBVIE INC. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2024 | This clinician | $4,900 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Subjects With Moderately To Severely Active Crohns Disease Who Have Inadequately Responded To Or Are Intolerant To Conventional and/Or Biologic Therapies · 2021 | This clinician | $4,800 |
| Takeda Pharmaceuticals U.S.A., Inc. · Verdict · 2025 | This clinician | $4,550 |
| Takeda Pharmaceuticals U.S.A., Inc. · Entyvio (Vedolizumab) Long-Term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab To Other Biologic Agents in Patients With Ulcerative Colitis Or Crohn'S Disease · 2025 | This clinician | $3,360 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Subjects With Crohns Disease Who Completed the Studies M14-431 Or M14-433 · 2021 | This clinician | $3,300 |
| Takeda Pharmaceuticals U.S.A., Inc. · Tak-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study To Evaluate the Efficacy and Safety of Oral Tak-279 in Subjects With Moderately To Severely Active Ulcerative Colitis · 2025 | This clinician | $2,970 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1, Open-Label, Randomized Parallel Group Study To Assess the Pharmacokinetics of Single Intravenous and Subcutaneous Injections of Vedolizumab Administered in Healthy Subjects · 2024 | Their institution | $2,870 |
| ABBVIE INC. · A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately To Severely Active Ulcerative Colitis · 2021 | This clinician | $2,400 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2020 | This clinician | $2,300 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2020 | This clinician | $2,300 |
| Eli Lilly and Company · A Phase 3 Multicenter Randomized Double-Blind Parallel Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2023 | This clinician | $2,200 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and An Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis · 2021 | This clinician | $2,200 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2024 | This clinician | $1,800 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2025 | This clinician | $1,800 |
| Eli Lilly and Company · A Phase 3 Multicenter Randomized Double-Blind Parallel-Arm Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2023 | This clinician | $300 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 77.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1962608364
- Licence
- CA A89127California A89127: Cancelled
- Trained
- University of New Mexico School of Medicine, 2001
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X)
- Mailing address
- 300 Pasteur Dr, Room A608, Stanford, CA, 94305
- NPI first listed
- 2007-06-22
- NPI last updated
- 2021-05-24
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.